275 related articles for article (PubMed ID: 20303470)
1. The lipid triad, or how to reduce residual cardiovascular risk?
Girard-Mauduit S
Ann Endocrinol (Paris); 2010 Mar; 71(2):89-94. PubMed ID: 20303470
[TBL] [Abstract][Full Text] [Related]
2. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. [Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].
Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC; González-Timón B; González-Juanatey JR
Med Clin (Barc); 2013 Nov; 141(10):430-6. PubMed ID: 23246165
[TBL] [Abstract][Full Text] [Related]
5. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
6. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study.
Leiter LA; Lundman P; da Silva PM; Drexel H; Jünger C; Gitt AK;
Diabet Med; 2011 Nov; 28(11):1343-51. PubMed ID: 21679231
[TBL] [Abstract][Full Text] [Related]
7. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
Stalenhoef AF; Davidson MH; Robinson JG; Burgess T; Duttlinger-Maddux R; Kallend D; Goldberg AC; Bays H
Diabetes Obes Metab; 2012 Jan; 14(1):30-9. PubMed ID: 21819519
[TBL] [Abstract][Full Text] [Related]
9. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease.
Windler E; Schöffauer M; Zyriax BC
Diab Vasc Dis Res; 2007 Jun; 4(2):136-42. PubMed ID: 17654448
[TBL] [Abstract][Full Text] [Related]
10. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
[TBL] [Abstract][Full Text] [Related]
11. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
[TBL] [Abstract][Full Text] [Related]
12. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
13. Catabolism of lipoproteins and metabolic syndrome.
Therond P
Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
[TBL] [Abstract][Full Text] [Related]
14. Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.
Ferrières J; Bérard E; Crisan O; Bongard V
Arch Cardiovasc Dis; 2010 May; 103(5):302-9. PubMed ID: 20619240
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
[TBL] [Abstract][Full Text] [Related]
16. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Bilz S
Ther Umsch; 2017; 74(8):445-453. PubMed ID: 29461147
[No Abstract] [Full Text] [Related]
18. [Atherogenic dyslipidemia and residual risk. State of the art in 2014].
Millán Núñez-Cortés J; Pedro-Botet Montoya J; Pintó Sala X;
Clin Investig Arterioscler; 2014; 26(6):287-92. PubMed ID: 25450326
[TBL] [Abstract][Full Text] [Related]
19. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
Díaz Rodríguez Á
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
[TBL] [Abstract][Full Text] [Related]
20. Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets.
Ng DS
Can J Diabetes; 2013 Oct; 37(5):319-26. PubMed ID: 24500559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]